We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

Corporate publications | Resources | Media | Grünenthal Group

Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.

... Research & Development

For us, innovation goes beyond drug development. Our innovation is built on expert knowledge of disease-pathophysiology’s, understanding of the patient, the use of big data and state-of-the-art technologies such as devices that result in innovative solutions for the patients need.

... Strategy

Our R&D pipeline is a source of great excitement – we currently have several new drug candidates and technologies in different phases of development.

... Pipeline

Our key innovation areas are pain and devices and technologies.

... Focus areas

As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.

... Clinical trials

Collaboration with the scientific community is central to our R&D strategy. Let’s work together – collaborate with us!

... Collaborate with us

Ambition is welcome at Grünenthal. Whether you’re a world-class scientist or a talented graduate, together we drive cutting-edge research projects and develop products of the future. Grünenthal offers a culture of opportunity. Join us!

... Jobs and career

From research scientists and high achieving graduates to experts in marketing and production, our open and inclusive culture helps everyone thrive.

... Meet our people

A distinct culture is central to the wellbeing of any organisation. We are Grünenthal has been vital in engaging new employees with our business and guiding our daily work.

... We are Grünenthal

Explore our media section and access a range of materials relating to our company, people, medicines and medical devices.

... Media

In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany.

... Press releases

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Corporate Publications

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of € 1.3 bn.

Grünenthal Report 2018/19

2018 was a decisive year for Grünenthal – both strategically and financially. We have advanced our pipeline, while further executing our strategy at high pace. This progress was made possible by our outstanding teams worldwide. Read more in the Grünenthal Report 2018/19.

... Find out more